<code id='CDB42BCACB'></code><style id='CDB42BCACB'></style>
    • <acronym id='CDB42BCACB'></acronym>
      <center id='CDB42BCACB'><center id='CDB42BCACB'><tfoot id='CDB42BCACB'></tfoot></center><abbr id='CDB42BCACB'><dir id='CDB42BCACB'><tfoot id='CDB42BCACB'></tfoot><noframes id='CDB42BCACB'>

    • <optgroup id='CDB42BCACB'><strike id='CDB42BCACB'><sup id='CDB42BCACB'></sup></strike><code id='CDB42BCACB'></code></optgroup>
        1. <b id='CDB42BCACB'><label id='CDB42BCACB'><select id='CDB42BCACB'><dt id='CDB42BCACB'><span id='CDB42BCACB'></span></dt></select></label></b><u id='CDB42BCACB'></u>
          <i id='CDB42BCACB'><strike id='CDB42BCACB'><tt id='CDB42BCACB'><pre id='CDB42BCACB'></pre></tt></strike></i>

          Home / explore / entertainment

          entertainment


          entertainment

          author:focus    Page View:39
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In